These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 31365750)
1. Management of Midostaurin-CYP3A4 Drug-Drug Interactions in Patients With Acute Myeloid Leukemia. Schlafer D Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365750 [No Abstract] [Full Text] [Related]
2. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report. Tollkuci E J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838 [TBL] [Abstract][Full Text] [Related]
3. Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use. Abdul-Hamil NA; Wong GC; Nagarajan C; Martinelli G; Cherchione C Minerva Med; 2020 Oct; 111(5):443-454. PubMed ID: 32955824 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML). Sechaud R; Sinclair K; Grosch K; Ouatas T; Pathak D Cancer Chemother Pharmacol; 2022 Jul; 90(1):19-27. PubMed ID: 35751657 [TBL] [Abstract][Full Text] [Related]
5. Midostaurin for the treatment of acute myeloid leukemia. Patnaik MM Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444 [TBL] [Abstract][Full Text] [Related]
6. Midostaurin in FLT3-mutated acute myeloid leukaemia. Das M Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736 [No Abstract] [Full Text] [Related]
7. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia. Stansfield LC; Pollyea DA Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600 [TBL] [Abstract][Full Text] [Related]
8. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive. Garcia JS; Percival ME Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055 [TBL] [Abstract][Full Text] [Related]
9. Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life. Menna P; Salvatorelli E; Del Principe MI; Perrone S; Pagano L; Marchesi F; Minotti G Chemotherapy; 2021; 66(1-2):47-52. PubMed ID: 33677444 [TBL] [Abstract][Full Text] [Related]
10. Midostaurin for patients with acute myeloid leukemia and FLT3 mutations. Levis MJ Clin Adv Hematol Oncol; 2019 Jun; 17(6):323-325. PubMed ID: 31437132 [No Abstract] [Full Text] [Related]
11. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin. Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990 [TBL] [Abstract][Full Text] [Related]
12. Midostaurin Gets FDA Nod for AML. Cancer Discov; 2017 Jul; 7(7):OF5. PubMed ID: 28526740 [TBL] [Abstract][Full Text] [Related]
13. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Luskin MR; DeAngelo DJ Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942 [TBL] [Abstract][Full Text] [Related]
14. FLT3 inhibitors in acute myeloid leukemia: Current and future. Thomas CM; Campbell P J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754 [TBL] [Abstract][Full Text] [Related]
15. Midostaurin approved for FLT3-mutated AML. Levis M Blood; 2017 Jun; 129(26):3403-3406. PubMed ID: 28546144 [TBL] [Abstract][Full Text] [Related]
16. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim M; Williams S Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051 [TBL] [Abstract][Full Text] [Related]
17. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. Dutreix C; Munarini F; Lorenzo S; Roesel J; Wang Y Cancer Chemother Pharmacol; 2013 Dec; 72(6):1223-34. PubMed ID: 24085261 [TBL] [Abstract][Full Text] [Related]
18. Closing in on targeted therapy for acute myeloid leukaemia. The Lancet Haematology Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709 [No Abstract] [Full Text] [Related]